Approval Year
Substance Class |
Nucleic Acid
Created
by
admin
on
Edited
Sat Dec 16 10:21:31 GMT 2023
by
admin
on
Sat Dec 16 10:21:31 GMT 2023
|
Nucleic Acid Subtype | |
Sequence Type | OLIGONUCLEOTIDE |
Record UNII |
ROV204583W
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C307
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
||
|
FDA ORPHAN DRUG |
535516
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
KL-44
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
C146805
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
m12182
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
1639325-43-1
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
10280
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
2265712
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
Givosiran
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
5354
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
DTXSID701027901
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
ROV204583W
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
ROV204583W
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY | |||
|
DB15066
Created by
admin on Sat Dec 16 10:21:31 GMT 2023 , Edited by admin on Sat Dec 16 10:21:31 GMT 2023
|
PRIMARY |
Sugar | Site Range | Site Count |
---|---|---|
2'-Fluoro-Ribose | 1_2-1_4;1_6;1_8;1_10;1_12;1_14;1_16;1_18;1_20;2_7;2_9;2_11;2_13;2_15;2_22 | 17 / 45 |
2'-O-Methyl-Ribose | 1_1;1_5;1_7;1_9;1_11;1_13;1_15;1_17;1_19;1_21-1_23;2_1-2_6;2_8;2_10;2_12;2_14;2_16-2_21 | 28 / 45 |
Linkage | Site Range | Site Count |
---|---|---|
Phosporothioate | 1_2-1_3;1_22-1_23;2_4-2_5 | 6 / 43 |
Phosphate | 1_4-1_21;2_4-2_22 | 37 / 43 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->INHIBITOR OF EXPRESSION |
Results in downregulation of ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels that are associated with acute porphyria attacks.
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Structural Modifications
Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
---|---|---|---|---|---|---|
NUCLEOTIDE SUBSTITUTION | [2_22] | X | CEMDISIRAN, TERMINAL SUGAR MODIFICATION- | CQQ59545BV |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|